Balchem Corp has recently released its 10-K report, detailing its operations and financial performance. The company, incorporated in 1967 and headquartered in Montvale, New Jersey, operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry, including specialty vitamin K2, microencapsulation solutions, and human grade choline nutrients. The Animal Nutrition & Health segment provides microencapsulated products and chelation technology for various animal species, along with essential nutrient choline chloride. The Specialty Products segment distributes performance gases and chemicals, including ethylene oxide and ammonia for the health care industry, as well as single-use canisters for sterilizing reusable devices.
In the "Risk Factors" section, Balchem Corp highlights the challenges it faces, such as supply chain disruptions due to geopolitical issues, inflationary patterns, and tariffs impacting certain raw materials. The company also emphasizes the importance of maintaining a strong reputation for product quality and customer service in the commodity-oriented choline chloride marketplace. Additionally, it notes the seasonal nature of its plant nutrition business within the Specialty Products segment, with the majority of sales occurring in the first half of the year based on the planting season in the northern hemisphere.
Balchem Corp discloses a total backlog of $53,365 at the end of 2025, reflecting an increase from the previous year. The company emphasizes its commitment to filling all orders in the current backlog during the 2026 fiscal year. It also acknowledges the competitive landscape across its segments, with competition based on product performance, customer support, quality, service, and price. The company's research and development expenses have increased over the years, demonstrating its continued investment in new products, improvements to existing products, and manufacturing processes.
The market has reacted to these announcements by moving the company's shares 1.64% to a price of $168.74. Check out the company's full 10-K submission here.
